Q2 2021 13F Holders as of 6/30/2021
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
81.1M
-
Number of holders
-
24
-
Total 13F shares, excl. options
-
6M
-
Shares change
-
+913K
-
Total reported value, excl. options
-
$110M
-
Value change
-
+$18.4M
-
Number of buys
-
14
-
Number of sells
-
-13
-
Price
-
$18.29
Significant Holders of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share (VRDN) as of Q2 2021
32 filings reported holding VRDN - Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share as of Q2 2021.
Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share (VRDN) has 24 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6M shares
of 81.1M outstanding shares and own 7.4% of the company stock.
Largest 10 shareholders include Ally Bridge Group (NY) LLC (860K shares), PERCEPTIVE ADVISORS LLC (795K shares), D. E. Shaw & Co., Inc. (720K shares), WELLINGTON MANAGEMENT GROUP LLP (579K shares), Point72 Asset Management, L.P. (396K shares), VANGUARD GROUP INC (354K shares), BVF INC/IL (350K shares), Ghost Tree Capital, LLC (350K shares), Cormorant Asset Management, LP (343K shares), and RA CAPITAL MANAGEMENT, L.P. (312K shares).
This table shows the top 24 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.